Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP vs EP in Neuroendocrine Carcinoma
NCT03168594Phase 2Terminated
- Sponsor
- Peking University
- Start
- Apr 2017
- Primary completion
- Feb 2019
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in neuroendocrine carcinoma (NEC) (2 arms), sponsored by Peking University. Primary endpoint: Overall Response Rate up to 24 months. Started Apr 2017; status: terminated.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03168594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168594.